Search
Search Results
-
Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer’s disease
BackgroundDysfunction of glial cell communication is involved in Alzheimer’s disease (AD) pathogenesis, and the recent study reported that astrocytic...
-
TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized Tau perspective
Microtubule-associated protein, Tau has been implicated in Alzheimer's disease for its detachment from microtubules and formation of insoluble...
-
An empirical measure of resilience explains individual differences in the effect of tau pathology on memory change in aging
Accurately measuring resilience to preclinical Alzheimer’s disease (AD) pathology is essential to understanding an important source of variability in...
-
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
BackgroundThe role of α-synuclein in dementia has been recognized, yet its exact influence on cognitive decline in non-demented older adults is still...
-
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe
Amyloid and tau biomarkers for Alzheimer’s disease are widely recognized diagnostic tools for the identification of Alzheimer’s disease pathology...
-
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes
BackgroundAlzheimer’s disease (AD) is a neurodegenerative disorder that manifests sequential Aβ and tau brain pathology with age-dependent onset....
-
Tyrosine phosphatase STEP61 in human dementia and in animal models with amyloid and tau pathology
Synaptic degeneration is a precursor of synaptic and neuronal loss in neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal...
-
Wolframin is a novel regulator of tau pathology and neurodegeneration
Selective neuronal vulnerability to protein aggregation is found in many neurodegenerative diseases including Alzheimer’s disease (AD). Understanding...
-
A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau
BackgroundAlzheimer’s disease (AD) is one of the most burdening diseases of the century with no disease-modifying treatment at this time. Nonhuman...
-
Nonlinear changes in delayed functional network topology in Alzheimer’s disease: relationship with amyloid and tau pathology
BackgroundAlzheimer’s disease is a neurodegenerative disorder associated with the abnormal deposition of pathological processes, such as amyloid-ß...
-
Alterations in iron content, iron-regulatory proteins and behaviour without tau pathology at one year following repetitive mild traumatic brain injury
Repetitive mild traumatic brain injury (r-mTBI) has increasingly become recognised as a risk factor for the development of neurodegenerative...
-
Association of small vessel disease with tau pathology
Emerging evidence suggests that small vessel disease (SVD) is a risk factor for clinical dementia and may contribute to AD neuropathological changes....
-
A brainstem to circadian system circuit links Tau pathology to sundowning-related disturbances in an Alzheimer’s disease mouse model
Alzheimer’s disease (AD) patients exhibit progressive disruption of entrained circadian rhythms and an aberrant circadian input pathway may underlie...
-
Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation
The noradrenergic locus ceruleus (LC) is the first site of detectable tau pathology in Alzheimer’s disease (AD), but the mechanisms underlying the...
-
Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer’s disease
Alzheimer’s disease neuropathologic change (ADNC) is clinically heterogenous and can present with a classic multidomain amnestic syndrome or focal...
-
Postmortem imaging reveals patterns of medial temporal lobe vulnerability to tau pathology in Alzheimer’s disease
Our current understanding of the spread and neurodegenerative effects of tau neurofibrillary tangles (NFTs) within the medial temporal lobe (MTL)...
-
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
BackgroundAntibody-based immunoassays have enabled quantification of very low concentrations of phosphorylated tau (p-tau) protein forms in...
-
Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
PurposeTau pathology is associated with concurrent atrophy and decreased cerebral blood flow (CBF) in Alzheimer’s disease (AD), but less is known...
-
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
BackgroundIn Alzheimer’s disease (AD), fibrillar tau initially occurs locally and progresses preferentially between closely connected regions....
